Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899413 · ClinicalTrials.gov registry record
Examining Transcutaneous Vagal Nerve Stimulation as a Facilitator of Social Bonding
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 160
- Enrollment target
NCT05899413: Completed study, sponsored by University of California, San Francisco.
NCT05899413 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05899413 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
This study aims to understand the role of the vagus nerve in promoting social bonding by using a non-invasive stimulation technique called transcutaneous vagal nerve stimulation (tVNS). The investigators will investigate whether tVNS can improve emotional, physiological, and behavioral experiences during and after social interactions. Couples will be randomly assigned to receive either tVNS or a sham stimulation during gratitude expression and problem-solving discussions. The investigators will measure their subjective evaluations of the interactions and capture their physiological and behavioral synchrony. This research will shed light on the processes involved in social connection and explore the potential of tVNS as a tool to enhance bonding in close relationships.
Primary Outcome
During the conversation, overall, I felt… (1: not at all positive, 7: extremely positive)
Interventions
- DEVICE Transcutaneous vagal nerve stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-02-17 |
| Est. Completion | 2024-07-31 |
What the finished NCT05899413 record still lists
NCT05899413 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Transcutaneous vagal nerve stimulation is the first listed.
NCT05899413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05899413 about?
NCT05899413 is a clinical study titled "Examining Transcutaneous Vagal Nerve Stimulation as a Facilitator of Social Bonding". This study aims to understand the role of the vagus nerve in promoting social bonding by using a non-invasive stimulation technique called transcutaneous vagal nerve stimulation (tVNS). The investigators will investigate whether tVNS can improve emotional, physiological, and behavioral experiences d...
What is the current status of trial NCT05899413?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2024-02-17. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05899413?
The interventions under investigation include: Transcutaneous vagal nerve stimulation (DEVICE).
Who is sponsoring clinical trial NCT05899413?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI